EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Citigroup Upgrades Gilead Sciences (NASDAQ:GILD) to Strong-Buy
ING Groep NV Buys 109,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Thursday's biggest stock analyst calls like Nvidia
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bell Bank
Prime Capital Investment Advisors LLC Sells 14,908 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Prices $3.5 Bln Of Senior Unsecured Notes
Gilead Prices $3.5 Billion of Senior Unsecured Notes | Morningstar
Company Website: https://www.gilead.com/ FOSTER CITY, Cali
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - November 14, 2024 - Zacks.com
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet - November 14, 2024 - Zacks.com
Citi sets $125 target on Gilead with Buy rating By Investing.com
5 Biggest Biotechnology ETFs in 2024
Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by Sumitomo Mitsui Trust Group Inc.
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD Cowen
TD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Victory Capital Management Inc. Sells 468,814 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Elanco boosts board with biopharma expert Dr. Stacey Ma By Investing.com
Elanco Strengthens Board of Directors with Addition of Stacey Ma | Morningstar
Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Atria Investments Inc Sells 3,854 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) Lowered to “Hold” Rating by Maxim Group
Elanco Animal Health Appoints Stacey Ma to its Board By Investing.com
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High Following Analyst Upgrade
Tyler Stone Wealth Management Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Colonial River Investments LLC
Gilead Sciences stock hits 52-week high at $98.34 By Investing.com
Moving toward response-adapted trials in oncology
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Crossmark Global Holdings Inc.
AIA Group Ltd Sells 18,541 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) & Taysha Gene Therapies (NASDAQ:TSHA) Head to Head Analysis
Assetmark Inc. Acquires 109,118 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
CWA Asset Management Group LLC Buys New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)
Principal Financial Group Inc. Buys 59,181 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
FY2024 EPS Estimate for Gilead Sciences Increased by Analyst
Oppenheimer Increases Gilead Sciences (NASDAQ:GILD) Price Target to $105.00
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences, Inc. Announces Quarterly Dividend of $0.77 (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $97.00 at Truist Financial
Gilead Sciences (NASDAQ:GILD) Rating Lowered to "Hold" at Maxim Group
Foster & Motley Inc. Sells 138 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Confluence Investment Management LLC Sells 11,734 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
M&G Plc Has $14.50 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Q1 EPS Estimates for Gilead Sciences Raised by Analyst
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
Royal Bank of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $81.00
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
Gilead Sciences Stock Near 52-Week High: Key Growth Drivers
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Barclays Analyst Says
Deseret Mutual Benefit Administrators Sells 2,474 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
General American Investors Co. Inc. Buys 25,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences (GILD) Shares Surge on Strong Q3 Earnings and Raised Forecast
Piper Sandler Increases Gilead Sciences (NASDAQ:GILD) Price Target to $105.00
Gilead Sciences (NASDAQ:GILD) Given “Hold” Rating at Needham & Company LLC
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results | Morningstar
Gilead Sciences (NASDAQ:GILD) Given "Hold" Rating at Needham & Company LLC
GILEAD SCIENCES APPOINTS PAUL PETRELLI TO VICE PRESIDENT AND GENERAL MANAGER IN CANADA
Zacks Research Expects Stronger Earnings for Gilead Sciences
Avidian Wealth Enterprises LLC Purchases 310 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Catalyst Capital Advisors LLC Sells 252 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Q3 2024 Gilead Sciences Inc Earnings Call Transcript
7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook - November 7, 2024 - Zacks.com
Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance | Morningstar
Gilead Sciences Inc. Q3 Profit Decreases, But Beats Estimates
Zacks Research Boosts Earnings Estimates for Gilead Sciences
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance | Morningstar
Gilead Sciences News | Markets Insider
Gulf International Bank UK Ltd Sells 4,422 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
BMO reiterates Gilead at Outperform with $94 target By Investing.com
Gladstone Institutional Advisory LLC Sells 9,014 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences' SWOT analysis: stock outlook hinges on HIV and oncology success By Investing.com
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? - November 5, 2024 - Zacks.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com
Gilead Sciences (NASDAQ:GILD) Sets New 1-Year High - Still a Buy?
Gilead stock touches 52-week high at $89.92 amid robust growth By Investing.com
10 Best Pharma Stocks To Buy Right Now
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis
Gilead Science to Report Q3 Earnings: What's in the Cards? - November 4, 2024 - Zacks.com
Conning Inc. Sells 79,724 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lowered by Private Management Group Inc.
Diversify Advisory Services LLC Has $265,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)
New York State Common Retirement Fund Has $143.58 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Mutual Advisors LLC
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - November 1, 2024 - Zacks.com
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by AustralianSuper Pty Ltd
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Catalyst Financial Partners LLC
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies | Morningstar
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2024 / Gilead Sci
Pallas Capital Advisors LLC Buys 2,069 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - October 31, 2024 - Zacks.com
New York State Teachers Retirement System Sells 41,052 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by New York State Teachers Retirement System
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting | Morningstar
Fortitude Family Office LLC Acquires 574 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences (GILD) to Release Quarterly Earnings on Wednesday
